<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12295">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02946879</url>
  </required_header>
  <id_info>
    <org_study_id>MGT004</org_study_id>
    <secondary_id>2016-000898-20</secondary_id>
    <nct_id>NCT02946879</nct_id>
  </id_info>
  <brief_title>Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)</brief_title>
  <official_title>Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno-associated Virus Vector (AAV2/5-OPTIRPE65) for Gene Therapy of Adults and Children With Retinal Dystrophy Owing to Defects in RPE65 (LCA2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MeiraGTx UK II Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syne Qua Non Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MeiraGTx UK II Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a longer-term follow-up study for patients who have been administered
      AAV2/5-OPTIRPE65 in the Phase I/II, open label, non-randomised, two-centre, dose escalation
      trial in adults and children with retinal dystrophy associated with defects in RPE65.

      The study is designed to collect data on longer-term safety and efficacy at 9-, 12-, 18-,
      24-, 36-, 48- and 60-month time-points following AAV2/5-OPTIRPE65 administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The follow up study is designed to collect data on longer-term safety and efficacy at 9, 12,
      18, 24, 36, 48 and 60 month time-points following AAV2/5-OPTIRPE65 administration in the
      OPTIRPE65 trial. Safety and efficacy is being assessed by clinical examination and
      investigations according to a pre-defined schedule of follow up visits. The OPTIRPE65 trial
      is an on-going open-label, Phase I/II dose-escalation study to determine the safety and
      efficacy of a subretinal administration of the Advanced Therapy Investigational Medicinal
      Product in participants with RPE65-related retinal dystrophy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Dose Escalation Trial of an Adeno-Associated Virus Vector(AAV2/5-OPTIRPE65) for Gene Therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events related to the subretinal administration of AAV2/5-OPTIRPE65 (administered in the OPTIRPE65 clinical trial).</measure>
    <time_frame>5 years</time_frame>
    <description>The primary research objective is to assess the longer term safety of AAV2/5-OPTIRPE65 administered to participants in the OPTIRPE65 trial, measured by the presence or absence of adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in the retinal function</measure>
    <time_frame>5 years</time_frame>
    <description>Improvement in the retinal function from baseline that is measurable by electroretinography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the visual function</measure>
    <time_frame>5 years</time_frame>
    <description>Any improvement in the visual function from baseline that is sustained for at least two consecutive assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life</measure>
    <time_frame>5 years</time_frame>
    <description>Improvement in the participant's quality of life which is measurable by EQ-5D-5L and vision specific QoL questionnaires</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Leber Congenital Amaurosis (LCA)</condition>
  <condition>Eye Diseases</condition>
  <condition>Eye Diseases, Hereditary</condition>
  <condition>Retinal Diseases</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AAV2/5-OPTIRPE65 vector will be administered at the single occasion to one eye only</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>AAV2/5-OPTIRPE65</intervention_name>
    <description>AAV2/5-OPTIRPE65 intraocular administration.</description>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are able to give informed consent or assent, with or without the guidance of their
             parent/guardian where appropriate.

          -  Were enrolled and treated in the prior open-label, Phase I/II, dose escalation study
             involving intraocular administration of AAV2/5-OPTIRPE65

          -  Are willing to adhere to the protocol and long-term follow up

        Exclusion Criteria:

          -  Individuals will be excluded if they are unwilling or unable to meet with the
             requirements of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Bainbridge, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie Bakobaki, MSc</last_name>
    <phone>+44 (0)20 3866 4320</phone>
    <email>julie.bakobaki@meiragtx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Morka, MSc</last_name>
    <phone>44 (0)20 3725 2350</phone>
    <email>anna.morka@meiragtx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moorfields Eye Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Connor</last_name>
      <phone>02075662821</phone>
      <email>Sophie.Connor@moorfields.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Neruban Kumaran, Dr</last_name>
      <email>neruban.kumaran@moorfields.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>James Bainbridge, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Acland GM, Aguirre GD, Bennett J, Aleman TS, Cideciyan AV, Bennicelli J, Dejneka NS, Pearce-Kelling SE, Maguire AM, Palczewski K, Hauswirth WW, Jacobson SG. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther. 2005 Dec;12(6):1072-82. Epub 2005 Oct 14.</citation>
    <PMID>16226919</PMID>
  </reference>
  <reference>
    <citation>Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, Cideciyan AV, Pearce-Kelling SE, Anand V, Zeng Y, Maguire AM, Jacobson SG, Hauswirth WW, Bennett J. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet. 2001 May;28(1):92-5.</citation>
    <PMID>11326284</PMID>
  </reference>
  <reference>
    <citation>Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. 2008 May 22;358(21):2231-9. doi: 10.1056/NEJMoa0802268. Epub 2008 Apr 27.</citation>
    <PMID>18441371</PMID>
  </reference>
  <reference>
    <citation>Bainbridge JW, Mehat MS, Sundaram V, Robbie SJ, Barker SE, Ripamonti C, Georgiadis A, Mowat FM, Beattie SG, Gardner PJ, Feathers KL, Luong VA, Yzer S, Balaggan K, Viswanathan A, de Ravel TJ, Casteels I, Holder GE, Tyler N, Fitzke FW, Weleber RG, Nardini M, Moore AT, Thompson DA, Petersen-Jones SM, Michaelides M, van den Born LI, Stockman A, Smith AJ, Rubin G, Ali RR. Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med. 2015 May 14;372(20):1887-97. doi: 10.1056/NEJMoa1414221. Epub 2015 May 4.</citation>
    <PMID>25938638</PMID>
  </reference>
  <reference>
    <citation>Balaggan KS, Duran Y, Georgiadis A, Thaung C, Barker SE, Buch PK, MacNeil A, Robbie S, Bainbridge JW, Smith AJ, Ali RR. Absence of ocular malignant transformation after sub-retinal delivery of rAAV2/2 or integrating lentiviral vectors in p53-deficient mice. Gene Ther. 2012 Feb;19(2):182-8. doi: 10.1038/gt.2011.194. Epub 2011 Nov 24.</citation>
    <PMID>22113317</PMID>
  </reference>
  <reference>
    <citation>Bennicelli J, Wright JF, Komaromy A, Jacobs JB, Hauck B, Zelenaia O, Mingozzi F, Hui D, Chung D, Rex TS, Wei Z, Qu G, Zhou S, Zeiss C, Arruda VR, Acland GM, Dell'Osso LF, High KA, Maguire AM, Bennett J. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther. 2008 Mar;16(3):458-65. doi: 10.1038/sj.mt.6300389. Epub 2008 Jan 22.</citation>
    <PMID>18209734</PMID>
  </reference>
  <reference>
    <citation>Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013 Feb 5;158(3):200-7. doi: 10.7326/0003-4819-158-3-201302050-00583.</citation>
    <PMID>23295957</PMID>
  </reference>
  <reference>
    <citation>Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleza-Jeric K, Laupacis A, Moher D. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013 Jan 8;346:e7586. doi: 10.1136/bmj.e7586.</citation>
    <PMID>23303884</PMID>
  </reference>
  <reference>
    <citation>Cideciyan AV, Aleman TS, Boye SL, Schwartz SB, Kaushal S, Roman AJ, Pang JJ, Sumaroka A, Windsor EA, Wilson JM, Flotte TR, Fishman GA, Heon E, Stone EM, Byrne BJ, Jacobson SG, Hauswirth WW. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15112-7. doi: 10.1073/pnas.0807027105. Epub 2008 Sep 22.</citation>
    <PMID>18809924</PMID>
  </reference>
  <reference>
    <citation>Cideciyan AV, Jacobson SG, Beltran WA, Sumaroka A, Swider M, Iwabe S, Roman AJ, Olivares MB, Schwartz SB, Komáromy AM, Hauswirth WW, Aguirre GD. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):E517-25. doi: 10.1073/pnas.1218933110. Epub 2013 Jan 22.</citation>
    <PMID>23341635</PMID>
  </reference>
  <reference>
    <citation>Cremers FP, van den Hurk JA, den Hollander AI. Molecular genetics of Leber congenital amaurosis. Hum Mol Genet. 2002 May 15;11(10):1169-76. Review.</citation>
    <PMID>12015276</PMID>
  </reference>
  <reference>
    <citation>Dekomien G, Epplen JT. Evaluation of the canine RPE65 gene in affected dogs with generalized progressive retinal atrophy. Mol Vis. 2003 Nov 11;9:601-5.</citation>
    <PMID>14627956</PMID>
  </reference>
  <reference>
    <citation>Ekesten B, Gouras P, Salchow DJ. Ultraviolet and middle wavelength sensitive cone responses in the electroretinogram (ERG) of normal and Rpe65 -/- mice. Vision Res. 2001 Sep;41(19):2425-33.</citation>
    <PMID>11483174</PMID>
  </reference>
  <reference>
    <citation>Hamel CP, Tsilou E, Pfeffer BA, Hooks JJ, Detrick B, Redmond TM. Molecular cloning and expression of RPE65, a novel retinal pigment epithelium-specific microsomal protein that is post-transcriptionally regulated in vitro. J Biol Chem. 1993 Jul 25;268(21):15751-7.</citation>
    <PMID>8340400</PMID>
  </reference>
  <reference>
    <citation>Jacobson SG, Acland GM, Aguirre GD, Aleman TS, Schwartz SB, Cideciyan AV, Zeiss CJ, Komaromy AM, Kaushal S, Roman AJ, Windsor EA, Sumaroka A, Pearce-Kelling SE, Conlon TJ, Chiodo VA, Boye SL, Flotte TR, Maguire AM, Bennett J, Hauswirth WW. Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol Ther. 2006 Jun;13(6):1074-84. Epub 2006 Apr 27.</citation>
    <PMID>16644289</PMID>
  </reference>
  <reference>
    <citation>Koenekoop RK. An overview of Leber congenital amaurosis: a model to understand human retinal development. Surv Ophthalmol. 2004 Jul-Aug;49(4):379-98. Review.</citation>
    <PMID>15231395</PMID>
  </reference>
  <reference>
    <citation>Le Meur G, Stieger K, Smith AJ, Weber M, Deschamps JY, Nivard D, Mendes-Madeira A, Provost N, Péréon Y, Cherel Y, Ali RR, Hamel C, Moullier P, Rolling F. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther. 2007 Feb;14(4):292-303. Epub 2006 Oct 5.</citation>
    <PMID>17024105</PMID>
  </reference>
  <reference>
    <citation>Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell'Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008 May 22;358(21):2240-8. doi: 10.1056/NEJMoa0802315. Epub 2008 Apr 27.</citation>
    <PMID>18441370</PMID>
  </reference>
  <reference>
    <citation>Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, Kay MA. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006 Mar;12(3):342-7. Epub 2006 Feb 12. Erratum in: Nat Med. 2006 May;12(5):592. Rasko, John [corrected to Rasko, John JE]; Rustagi, Pradip K [added].</citation>
    <PMID>16474400</PMID>
  </reference>
  <reference>
    <citation>Marlhens F, Bareil C, Griffoin JM, Zrenner E, Amalric P, Eliaou C, Liu SY, Harris E, Redmond TM, Arnaud B, Claustres M, Hamel CP. Mutations in RPE65 cause Leber's congenital amaurosis. Nat Genet. 1997 Oct;17(2):139-41.</citation>
    <PMID>9326927</PMID>
  </reference>
  <reference>
    <citation>NIH, Common terminology criteria for adverse events (CTCAE) Version 4.0, 2009, US Department of Health and Human Services; National Institutes of Health; National Cancer Institute: Washington DC.</citation>
  </reference>
  <reference>
    <citation>Nowrouzi A, Penaud-Budloo M, Kaeppel C, Appelt U, Le Guiner C, Moullier P, von Kalle C, Snyder RO, Schmidt M. Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver. Mol Ther. 2012 Jun;20(6):1177-86. doi: 10.1038/mt.2012.47. Epub 2012 Mar 27.</citation>
    <PMID>22453768</PMID>
  </reference>
  <reference>
    <citation>Perrault I, Rozet JM, Gerber S, Ghazi I, Leowski C, Ducroq D, Souied E, Dufier JL, Munnich A, Kaplan J. Leber congenital amaurosis. Mol Genet Metab. 1999 Oct;68(2):200-8. Review.</citation>
    <PMID>10527670</PMID>
  </reference>
  <reference>
    <citation>Redmond TM, Yu S, Lee E, Bok D, Hamasaki D, Chen N, Goletz P, Ma JX, Crouch RK, Pfeifer K. Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. Nat Genet. 1998 Dec;20(4):344-51.</citation>
    <PMID>9843205</PMID>
  </reference>
  <reference>
    <citation>Stieger K, Colle MA, Dubreil L, Mendes-Madeira A, Weber M, Le Meur G, Deschamps JY, Provost N, Nivard D, Cherel Y, Moullier P, Rolling F. Subretinal delivery of recombinant AAV serotype 8 vector in dogs results in gene transfer to neurons in the brain. Mol Ther. 2008 May;16(5):916-23. doi: 10.1038/mt.2008.41. Epub 2008 Mar 11.</citation>
    <PMID>18388922</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 22, 2017</lastchanged_date>
  <firstreceived_date>July 22, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Leber Congenital Amaurosis</mesh_term>
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Retinal Dystrophies</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Eye Diseases, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
